https://www.live-feeds.com/feed/what-moderna-must-do-to-take-its-stock-to-the-next-levelContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/what-moderna-must-do-to-take-its-stock-to-the-next-levelhttps://www.live-feeds.com/feed/what-moderna-must-do-to-take-its-stock-to-the-next-level#u52730Mon, 31 Aug 2026 04:16:23 +0000Moderna's stock performance hinges on its ability to transition from a COVID-19 focus to a broader oncology portfolio. The company's mRNA vaccine for melanoma, developed with Merck, shows significant clinical potential but faces challenges including misinformation and operational barriers. Moderna plans to issue $2.0 billion in convertible senior notes, with an option for initial purchasers to acquire another $300 million.Why it mattersModerna's shift towards using mRNA technology for cancer prevention and treatment is crucial for its future growth. The company's ability to https://www.live-feeds.com/feed/what-moderna-must-do-to-take-its-stock-to-the-next-levelhttps://www.live-feeds.com/feed/what-moderna-must-do-to-take-its-stock-to-the-next-level#u49926Thu, 27 Aug 2026 10:46:19 +0000Moderna and Merck have developed an mRNA vaccine designed to stop melanoma from returning. This treatment represents a shift toward using mRNA technology for cancer prevention and treatment. While the clinical potential is significant, the path to widespread adoption faces challenges including mRNA misinformation and operational barriers to wide use. The company's stock performance depends on its ability to transition from a COVID-19 focus to a broader oncology portfolio.Why it mattersThe success of mRNA technology during the pandemic provided a blueprint for personalized cancer vaccines.